Penumbra PEN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Embolization and Access | $120.84M+23.8% | —— | $118.26M+22.0% | $109.2M+13.9% | $97.6M+7.3% | |
| Thrombectomy | $253.92M+12.1% | $254.7M+15.7% | $236.42M+15.8% | $230.26M+13.1% | $226.54M+20.7% | |
| Revenue by Geography | ||||||
| International | $78.37M+16.5% | —— | —— | —— | $67.28M-8.0% | |
| United States | $296.39M+15.4% | $299.05M+20.6% | $275.03M+21.5% | $260.82M+19.5% | $256.86M+22.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Penumbra break its business down?
- Penumbra (PEN) reports revenue by product across 3 parts — Embolization and Access, Embolization and Other and Thrombectomy. Each is extracted from the segment footnotes and tracked over time.
- Where does Penumbra's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Penumbra's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
